



PRESS RELEASE

Beactica appoints Dr Evert Homan as Chief Operating Officer

Uppsala, Sweden, 3 September 2010

Beactica, the leading Swedish fragment-based drug discovery company, today announced the promotion of Dr Evert Homan to Chief Operating Officer. Evert has been with the Company since 2008 when he joined from Biovitrum. He has more than ten years experience from the international pharmaceutical industry and a broad knowledge of the preclinical small-molecule drug discovery process.

“Evert is an important addition to the Company’s management team in an exciting time when the demand for Beactica’s expertise is higher than ever“ said Beactica CEO, Dr Per Källblad. “He will be a key asset in our continued quest for research excellence”.

Dr Evert Homan holds an M.Sc. in Pharmacy (1993) and a Ph.D. (1998) in Medicinal Chemistry from Groningen University in the Netherlands. He worked as a Postdoctoral Scientist at Pharmacopeia, Inc., Princeton, NJ (1999), before joining Pharmacia in Stockholm, Sweden, as a computational chemist (2000). From 2001 until joining Beactica, he worked at Biovitrum – a spin-off company from Pharmacia – where he was involved in over a dozen early drug discovery projects. During this period he also worked as chemistry team leader for lead generation projects and was involved in defining new disease area strategies as well as target identification.

For additional information please contact Dr Per Källblad, Beactica CEO, +46 18 560880.

About Beactica

Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the biophysical interaction of molecules in order to generate novel therapeutics. Beactica’s Sprint™ drug discovery platform efficiently integrates surface plasmon resonance (SPR) and molecular design to accelerate the identification and optimization of high-quality lead compounds. The company was spun out of Uppsala University in August 2006. As well as providing services and building collaborations with external companies, Beactica is progressing its own drug discovery programmes of small molecule therapeutics. For more information about Beactica, please visit www.beactica.com.